FOCUS ON ALZHEIMER'S DISEASE AND RELATED DISORDERS
not well-established medication is prescribed for the timelimited treatment of an Alzheimer's patient's neuropsychiatric symptoms, monitor the patient's response and adjust the medication accordingly. As recently suggested by a large study evaluating the cost-effectiveness of atypical antipsychotics in community-dwelling patients with Alzheimer's disease, 1 these and other medications may help some patients but not others, harm some patients but not others, or, of course, produce a combination of beneficial or adverse effects that need to be monitored and managed accordingly.
Finally, there is this challenge, too often ignored or inadequately addressed: How does one best help patients and families facing the most advanced stages of Alzheimer's disease? In this issue, Paul Kettl reviews several commonly confronted end-of-life care challenges, along with the important roles that the psychiatrist can play in working with families and other medical and nonmedical caregivers. He suggests how the psychiatrist can help patients and families anticipate and proactively address some of these challenges, and he reminds us of the extraordinary opportunity to maximize the comfort and quality of life of patients and families during this difficult time. His review emphasizes the importance of communicating with the family throughout the course of the patient's illness, helping them find appropriate resources for their nonmedical needs, facilitating advanced care directives when the patient may be able to participate in medical decisions and proxy decisions by family members later on, addressing commonly encountered physical problems in the most palliative way, and considering the possibility of hospice care.
For every challenge, there is an opportunity: the opportunity to evaluate slowing and prevention therapies for Alzheimer's disease in the most productive, rigorous, and costeffective way; the opportunity to find more effective and better tolerated treatments for our patients' neuropsychiatric symptoms and use them in the most thoughtful and empirically individualized way; and the opportunity to address the unmet nonmedical needs of patients and families throughout the course of their illness. If you have suggestions or comments regarding "Focus on Alzheimer's Disease and Related Disorders," please feel free to contact me at Eric.Reiman@bannerhealth.com.
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